Beyond insulin: Duopharma’s next act


Wan Amir-Jeffery: The ultimate objective is to generate higher earnings and ensure a good product mix that will contribute positively to our margins.

Duopharma Biotech Bhd’s loss of lead-supplier status in Malaysia’s government human insulin contract has raised questions over whether one of the country’s most established pharmaceutical players is beginning to lose ground in a segment it helped anchor for years.

While Pharmaniaga Bhd’s RM281.67mil insulin contract win changes market optics, it is not projected to fundamentally alter Duopharma’s earnings trajectory.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Doubling down on productivity
Towards a true Silicon Valley
Growth holds, risks loom
MISC’s RM3bil Yinson gamble
Ringgit expected to trade with slight positive bias next week
118 Mall celebrates year-end festivities with the Living Storybook
Timber's new twist
Coach, Ralph Lauren defy China slump�
Malaysia’s 3Q26 property reality check
Old drains and water strains

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read